Last reviewed 2026-04-20 · How we verify

Spasmopriv (FENOVERINE)

Phase 3 active Small molecule Quality 19/100

Spasmopriv (generic name: FENOVERINE) is a fenoverine drug. It is currently in Phase 3 development.

Fenoverine works by interacting with the muscarinic acetylcholine receptor, a key component in the parasympathetic nervous system.

Spasmopriv, also known as Fenoverine, is a small molecule drug in the fenoverine class. Its exact target is unknown, but it is used to treat certain conditions. Unfortunately, there is limited information available on its commercial status, approved indications, and pharmacokinetic properties. Further research is needed to fully understand its mechanism of action and safety profile. As a result, it is not widely used or recognized in the pharmaceutical industry.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FENOVERINE
Drug class	fenoverine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 3

Mechanism of action

Imagine your nervous system as a balance between two opposing forces: the sympathetic nervous system, which is like the accelerator in a car, and the parasympathetic nervous system, which is like the brake. Fenoverine helps to calm down the parasympathetic nervous system, which can help to relieve muscle spasms and other conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparative Efficacy and Safety of Fenoverine (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Spasmopriv CI brief — competitive landscape report
Spasmopriv updates RSS · CI watch RSS

Frequently asked questions about Spasmopriv

What is Spasmopriv?

Spasmopriv (FENOVERINE) is a fenoverine drug.

How does Spasmopriv work?

Fenoverine works by interacting with the muscarinic acetylcholine receptor, a key component in the parasympathetic nervous system.

What is the generic name of Spasmopriv?

FENOVERINE is the generic (nonproprietary) name of Spasmopriv.

What drug class is Spasmopriv in?

Spasmopriv belongs to the fenoverine class. See all fenoverine drugs at /class/fenoverine.

What development phase is Spasmopriv in?

Spasmopriv is in Phase 3.

Drug class: All fenoverine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing